Results of EIT Health InnoStars Start-Up Amplifier pre-selection round

The pre-selection round of EIT Health Start-Up Amplifier Programme is closed: 14 promising start-ups coming from InnoStars and EIT Health RIS region are chosen for the next stage.

This year, EIT Health began the start-up searching for the EIT Health Start-Up Amplifier Programme 2022, which aims to find exceptional biotech, medtech or digital health projects and innovative creators in the field of healthcare. 14 start-ups from among 50 application advanced to the next part of the contest in the pre-selection round. The shortlisted start-ups will receive a €2000 voucher for the assistance from the EIT Health Mentoring & Coaching Network, and a possibility to participate on  EIT Health Matchmaking event.

“It is always a great feeling to launch a programme because we know that this is the beginning of a journey for the participating teams – a journey that will be followed and accompanied by EIT Health all along the way. Our goal is to support, help and mentor the teams in EIT Health Start-Up Amplifier programme and help them develop their healthcare innovations that can contribute to the improvement of the healthcare systems in Europe,” said Mikolaj Gurdala, InnoStars Manager & Innovation Manager, EIT Health InnoStars.

The list of selected start-ups:

IMMAGINA BioTechnology S.r.l. (Italy): produces research tools for gene expression analysis at the ribosomal level. Their CircAID-p-seq technology provides everything from a research-use-only kit for gene expression studies to a new lab-developed test for in-vitro diagnostics companies working on breast and prostate cancer.

Nanofaber srl (Italy): develops an innovative portfolio of materials and nanotechnologies oriented towards the treatment of chronic diseases. MICROSPONGE, their main asset, is a micro-thin material offering high clinical potential, with applications for pharmaceutics, drug delivery and medical devices.

PELVIFLY (Poland): PelviFly enables safe and effective pelvic floor training using the device and mobile application. Depending on the chosen service option, the users can train themselves, with the support of advanced algorithms or under the remote care of a specialist who has insight into the results and prepares an individual exercise plan.

Sineko Global Kft. (Hungary): helps radiologists with GRAID software, an AI-supported structured reporting system for cross-border teleradiology. The solution allows for fast, easy sharing of radiology results and thereby aims to decrease reporting time and improve diagnostic quality.

Mysurable LTD (Italy): produces mioTest®, a comprehensive, portable, and automated system to evaluate muscular performance to diagnose sarcopenia, a syndrome characterised by the loss of muscle mass. Along with diagnosing the problem, the solution can suggest personalised treatment options.

Promptly Health (Portugal): Libra – a digital platform for promoting and sustaining healthy behaviours in obesity by Promptly Health, Centre for Health and Social Justice in further support of the University of Porto.

Semantic Intelligence (Latvia): Semantic Intelligence develops Artificial Scientist – an AI-driven search engine for drug discovery scientists to help accelerate R&D basic research processes. Artificial Scientist is the industry’s first solution using a cross-language approach (English, Russian, Chinese and Japanese), which allows scientists to find previously undiscovered knowledge on a particular research topic in four languages simultaneously.

BestHealth4U (Portugal): BestHealth4U received the first prize at Start-ups Meet Pharma 2019 for their revolutionary new technology Bio4Skin, a biomedical adhesive. The team specialises in the R&D of new technology solutions for unmet health needs. The company’s first product, Bio2Skin, uses the natural features of the skin to allow for strong yet gentle adhesion, thereby avoiding Medical Adhesive-Related Skin Injuries (MARSI).

NU-RISE (Portugal): drives the next-generation of radiotherapy by providing real-time patient dose tracking for precise, autonomous and safer radiation oncology.

Fetal Health (Hungary): the team developed a new, currently on the market, non-existent gynaecological diagnostic medical device, with which the death and injury of new-borns could be significantly reduced by measuring the fatal EEG and ECG waveforms during pregnancy and labour. The device alerts the medical team when the baby inside the mother’s womb doesn’t receive enough oxygen.

PhoenixOrthosis (Hungary): the Hungarian team supports stroke survivors to make their lives easier and rehabilitation more effectively. The solution is an active hand-finger spasm orthosis. It utilizes breakthrough technologies to partially recover the missing opening function. The team is on a mission to shorten the time to regain the highest possible quality of the activities of daily living. It is a 100% customized slim-fit device designed to support the patient at any time.

MB Emplastrum (Lithuania): EmPlastrum would like to develop a device that is a flexible, silicon patch with a small screen on top with integrated UVB LED lights. The innovation allows shifting psoriasis treatment from hospital to home and makes the treatment itself more comfortable compared to current, time-consuming methods patients are not satisfied with, based on survey responses and research.

ENDOBIOS (Portugal): ENDOBIOS® was founded in September 2018 after ground-breaking datasets showing that our drug candidate, a new natural compound derived from a marine fungus and currently in preclinical trials, could be potentially used against multiple neuropathies. ENDOBIOS® is developing a proprietary screening method for the specific induction of novel neuropathic agents from environmental microbial sources.

Prometheus (Italy): Prometheus was founded in 2018 thanks to the support of Democenter-Sipe foundation, TPM Cube (incubator of Mirandola). Prometheus is a start-up that creates and sells 3D living human tissues for regenerative medicine and pharmaceutical tests for new drugs, through a technology (a 3D Bioprinter) developed by Prometheus team. This technology makes it possible to create tissues almost equal to the human ones. The innovative production process allows for completely controlled printing of cells that remain alive throughout the process.

More about EIT Health Start-Up Amplifier programme:

With the Start-up Amplifier programme, EIT Health’s aim is to give top start-ups an opportunity to play a key role in EIT Health Innovation Projects and help them establish cooperation with research centres, hospitals or health service providers throughout Europe by using the possibilities of the EIT Health community.